English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

Ability to License SciClone’s Novel Anticancer Agent for the China Market

May. 11, 2016

Ability Pharmaceuticals and SciClone Pharmaceuticals have entered into an agreement, granting SciClone an exclusive license to develop and market the novel anticancer ABTL0812 in China and some adjacent territories.

Under the terms of the agreement, Ability will receive an upfront payment and research funding as well as development, regulatory and sales milestone payments, potentially totaling more than $20 million; AbilityPharma will also be eligible to receive royalties on sales.